Only two major studio apartment films ar currently existence shot in Southern California, DreamWorks' Transformers Revenge of the Fallen and Sony's Angels & Demons , the Los Angeles Times discovered today (Tuesday), blaming the production lag partly on scheduling decisions made a year ago in
Saturday, 30 August 2008
Wednesday, 20 August 2008
Brazilian singer, songwriter Dorival Caymmi dies
SAO PAULO, Brazil �
More info
Brazilian composer and vocalizer Dorival Caymmi, who catapulted to celebrity when Carmen Miranda performed one of his songs in 1938, died Saturday. He was 94.
He died of kidney cancer and multiple organ failure in his Rio de Janeiro home, his granddaughter Stela Caymmi told the Globo TV network.
Caymmi's lyrics were inspired by the beautiful women and folklore of the northeastern Brazilian state of Bahia, where he was born. A deep, velvety vocalism also helped make him one of the country's most honey artists.
Among more than hundred songs he composed, "O que e que a Baiana tem" was immortalized by Miranda.
His song "Das Rosas" was translated into English as "And Roses and Roses" by American lyricist Ray Gilbert and sung by Andy Williams and Perry Como, among others.
Caymmi's sons Dori and Danilo and daughter Nana are all prominent musicians who got their begin accompanying their father on the stage and in the transcription studio.
More info
Sunday, 10 August 2008
Phase 3 Trial With Investigational Hepatitis B Vaccine (HEPLISAV) Met Primary Endpoint
�Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV�, an investigational hepatitis B virus (HBV) vaccine, to a presently marketed HBV vaccine, Engerix-B� (1). The study achieved its master endpoint. HEPLISAV is beingness jointly developed by Dynavax and Merck for use in adults and in patients with end stage renal disease.
This study, called PHAST (Phase 3 HeplisAv Short-regimen Trial), evaluated a two-dose regimen of HEPLISAV administered at 0 and 1 month compared to a three-dose regimen of Engerix-B� administered at 0, 1 and 6 months. The primary endpoint was the proportion of subjects wHO developed protective antibodies to hepatitis B after government. In PHAST, 95.1 percent of subjects world Health Organization received deuce doses of HEPLISAV (n=1,819) developed protective antibodies to hepatitis B when measured at 12 weeks versus 81.1 percent of subjects who received three doses of Engerix-B� (n=608) when measured at 28 weeks. The multi-center study evaluated 2,427 subjects from 11 to 55 age of age in Canada and Germany. Results of additional analyses from this trial will be presented in the future.
As previously disclosed, the U.S. Food and Drug Administration (FDA) set a clinical hold on the iI Investigational New Drug (IND) Applications for HEPLISAV that is quiet in effect. In issuing the clinical hold, the FDA requested a review of clinical and presymptomatic safety data for HEPLISAV. Additionally, the FDA requested all uncommitted information around a single case of Wegener's granulomatosis reported in this Phase 3 trial.
HEPLISAV is based on Dynavax's proprietary immunostimulatory episode (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to induce an innate immune reply. HEPLISAV combines ISS with HBV surface antigen (HBsAg) and is designed to enhance the speed of protection.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and keep infectious diseases, allergy, malignant neoplastic disease, and chronic inflammatory diseases using various, proprietary approaches that modify immune organization responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the power of the immune system to fight disease and control chronic inflammation. Our clinical intersection candidates include: HEPLISAV, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for metastatic colorectal cancer; and therapies for hepatitis B and C. Our presymptomatic asthma and COPD
This study, called PHAST (Phase 3 HeplisAv Short-regimen Trial), evaluated a two-dose regimen of HEPLISAV administered at 0 and 1 month compared to a three-dose regimen of Engerix-B� administered at 0, 1 and 6 months. The primary endpoint was the proportion of subjects wHO developed protective antibodies to hepatitis B after government. In PHAST, 95.1 percent of subjects world Health Organization received deuce doses of HEPLISAV (n=1,819) developed protective antibodies to hepatitis B when measured at 12 weeks versus 81.1 percent of subjects who received three doses of Engerix-B� (n=608) when measured at 28 weeks. The multi-center study evaluated 2,427 subjects from 11 to 55 age of age in Canada and Germany. Results of additional analyses from this trial will be presented in the future.
As previously disclosed, the U.S. Food and Drug Administration (FDA) set a clinical hold on the iI Investigational New Drug (IND) Applications for HEPLISAV that is quiet in effect. In issuing the clinical hold, the FDA requested a review of clinical and presymptomatic safety data for HEPLISAV. Additionally, the FDA requested all uncommitted information around a single case of Wegener's granulomatosis reported in this Phase 3 trial.
HEPLISAV is based on Dynavax's proprietary immunostimulatory episode (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to induce an innate immune reply. HEPLISAV combines ISS with HBV surface antigen (HBsAg) and is designed to enhance the speed of protection.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and keep infectious diseases, allergy, malignant neoplastic disease, and chronic inflammatory diseases using various, proprietary approaches that modify immune organization responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the power of the immune system to fight disease and control chronic inflammation. Our clinical intersection candidates include: HEPLISAV, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for metastatic colorectal cancer; and therapies for hepatitis B and C. Our presymptomatic asthma and COPD
Subscribe to:
Posts (Atom)